2022_Oct_PODD_Boston_ Skyscraper2

Tarsa Therapeutics

Tarsa Therapeutics developed TBRIA™, an oral formulation of calcitonin for postmenopausal osteoporosis. Rights to TBRIA have been acquired by R-Pharm JSC, whose US subsidiary is responsible for the continuing clinical development of TBRIA and subsequent regulatory submissions.


Headquarters
8 Penn Center
1628 John F Kennedy Boulevard
Suite 1400
Philadelphia
PA 19103-2124
United States

Phone / Contact

T: +1 267 273 7940
F: +1 267 273 7950
Top